Anas Younes

16PUBLICATIONS
129CO-AUTHORS
Molecular targetsHaematological tumoursRadiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Dec 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

|Sep 05, 2024
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.

Ana Portelinha, Shenqiu Wang, Sara Parsa

|Oct 29, 2023
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.

Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran

|Mar 19, 2023
Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.

Ana Portelinha, Mariana da Silva Ferreira, Tatiana Erazo

|Jan 16, 2023
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

David Qualls, Ariela Noy, David Straus

|Sep 27, 2022
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.

Tatiana Erazo, Chiara M Evans, Daniel Zakheim

Pageof 3

Frequent Collaborators

9 joint publications

Connie Lee Batlevi

7 joint publications

Ahmet Dogan

4 joint publications

Maria Lia Palomba

4 joint publications

Venkatraman Seshan